

ABSTRACT OF THE DISCLOSURE

An antiviral agent comprising an altered *MAB1*, *MAB2*, *MAB3*, or *OLE1* gene, gene homologs or related genes is disclosed. In another embodiment, the present invention is a method of creating a virus resistant organism comprising creating a transgenic organism comprising an antiviral agent selected from the group of altered *MAB1* genes, *MAB2* genes, *MAB3* genes or *OLE1* genes, homologs of these genes, related genes and combinations of these genes and homologs.